Failure of Activated Prothrombin Complex Concentrates in a Hemophiliac With an Anti-Factor VIII Antibody
- Philip M. Blatt, MD;
- Gilbert C. White II, MD;
- Campbell W. McMillan, MD;
- William P. Webster, DDS
Since this article does not have an abstract, we have provided the first 150 words of the full text.
Excerpt
IN APPROXIMATELY 15% of patients with severe hemophilia A who receive multiple transfusions, anti— factor VIII antibodies develop (C. W. McMillan, MD, S. S. Shapiro, MD, J. Lazerson, MD, unpublished data, 1983). Control of hemorrhagic episodes in these patients is often difficult and unsatisfactory. Various methods of treatment have been developed for such patients.1,2 Most recently, activated prothrombin complex concentrates (PCCs) have been described as efficacious in controlling hemorrhage in patients with an inhibitor. Two preparations of activated PCC have been developed: Autoplex (anti-inhibitor coagulant complex) and FEIBA (factor eight inhibitor bypassing activity). In published trials, response to treatment with Autoplex for major and minor bleeds ranged from excellent to fair with no treatment failures,2 while FEIBA was judged to be effective in control of joint and muscle bleeding in 64% of treatment episodes.3 The purpose of this report is to describe the failure of Autoplex to
Footnotes
-
Reprint requests to Division of Hematology, University of North Carolina School of Medicine, 417 Clinical Sciences Bldg 229H, Chapel Hill, NC 27514 (Dr White).
